Using GPT-4 to annotate the severity of all phenotypic abnormalities within the human phenotype ontology - Top-Institutions - MDSpire

Using GPT-4 to annotate the severity of all phenotypic abnormalities within the human phenotype ontology

  • By

  • Kitty B. Murphy

  • Brian M. Schilder

  • Nathan G. Skene

  • May 21, 2026

  • 0 min

Share

Top Institutions in General Medicine

Brief introduction explaining scope and methodology.

  • #1

    Icahn School of Medicine at Mount Sinai
    Icahn School of Medicine at Mount Sinai

    New York, New York

    Key Differentiators

    • Genetics
    • Computational Phenotyping

  • #2

    Baylor College of Medicine
    Baylor College of Medicine

    Houston, Texas

    Key Differentiators

    • Genetics
    • Translational Medicine

  • #3

    UCL Queen Square Institute of Neurology Dementia Research Centre
    UCL Queen Square Institute of Neurology Dementia Research Centre

    London, England

    Key Differentiators

    • Neurology
    • Dementia Research

  • #4

    ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) Research Study
    ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) Research Study

    Chicago, Illinois

    Key Differentiators

    • Neurology
    • Frontotemporal Degeneration

  • #5

    University of Oslo
    University of Oslo

    Oslo, Norway

    Key Differentiators

    • Genetics
    • Clinical Research

Original Source(s)

Using GPT-4 to annotate the severity of all phenotypic abnormalities within the human phenotype ontology

  • by Kitty B. Murphy, Brian M. Schilder, Nathan G. Skene

  • May 21, 2026

Related Content

The Missing Piece in the Dark Metabolome Puzzle?

Microdroplets formed during electrospray ionization may trigger chemical reactions that help explain a substantial portion of the “dark metabolome” – though some researchers question their relevance under typical metabolomics conditions

App-based prevention of preschooler unintentional injury in rural China: a cluster randomized controlled trial

America needs more clinics of last resort for patients who can’t get answers